Q2
CCCC — Q2 2026 Financial Report Analysis
C4 Therapeutics' Q2 2026 net loss narrowed 9% to $23.6M while loss per share halved on an 84% larger share count; a $20M Roche upfront and $33.5M stock sale lifted cash to $300.4M, but runway guidance stayed at end-2028.